Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 39

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 39
---
 consideration at the Special Meeting as contemplated by this proxy statement/prospectus. Interests of DiamiR Directors and Officers in the Merger In considering the recommendation of the DiamiR Board with respect to approving the Merger, stockholders should be aware that DiamiR directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of DiamiR stockholders generally. These interests may present them with actual or potential conflicts of interest, and these interests, to the extent material, are described below. From June 2020 through April 2023, Kira Sheinerman, one of the founders and the Executive Director of DiamiR, served as senior strategic consultant to Aptorum, which role included reviewing therapeutic and diagnostic opportunities, and making industry and academia introductions for Aptorum. Kira Sheinerman currently hold 2,772shares of Aptorum. The DiamiR Board was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the DiamiR stockholders approve the Merger as contemplated by this proxy statement/prospectus. Governance of the Combined Company Following the Merger Headquarters Aptorum and DiamiR have agreed that the Combined Company will be headquartered at DiamiR’s current corporate office in Princeton, New Jersey. Charters and Bylaws [] Board of Directors Immediately following the Merger, the Combined Company board of directors will be composed of five (5) members, two (2) of whom have been designated by DiamiR and three (3) of whom has been designated by Aptorum. Effective as of the Effective Time, the Aptorum board of directors will appoint the following DiamiR designees: Kira Sheinerman, Ph.D., MBA. and [], and the following Aptorum designee: Ian Huen, Justin Wu, and Douglas Arner to the board of directors of the Combined Company. Ian Huen is expected to be appointed as Chair of the Board of the Combined Company. Alidad Mireskandari, Ph.D., MBA will be appointed as a non -votingobserver to the Board of the Combined Company. The current staggered structure of the Aptorum Board will adjust to a single class of directors for the Combined Company following the completion of the Merger. 7

Executive Management Immediately following the Merger, the executive management team of the Combined Company is expected to consist of members of